Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Meditsinskiy sovet = Medical CouncilOpen Access

Role of the immunotherapy in the treatment of biliary tract cancers: Review of current clinical trials and retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ЕLЕ. V. LedinVSV. I. StolyarovEEE.O.Chuykova E.O.Chuykova

Discussion

Loading...

Member takes

Overview

Retrospective analysis assesses overall survival and efficacy of chemoimmunotherapy in cholangiocarcinoma, highlighting potential benefits.

Key Points

  • The median overall survival for patients receiving the treatment was 14.0 months, indicating promising outcomes.
  • In this analysis, 39% of patients experienced grade 3–4 adverse events, suggesting a need for careful monitoring.
  • The objective response rate for chemoimmunotherapy was 25%, which reflects real-world efficacy consistent with international data.
  • Combined treatment of gemcitabine and cisplatin with PD-1/PD-L1 inhibitors may significantly enhance survival for cholangiocarcinoma.

Cite This Study

Ledin et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64793dd6https://doi.org/10.21518/ms2025-194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chemoimmunotherapy in Advanced Biliary Tract Cancers: A Meta-Analysis of Clinical Outcomes2025
  2. 2Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis2025
  3. 3Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies2025
  4. 4Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer: A retrospective real-world study2025
  5. 5Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study2025